Navigation Links
Umbilical cord blood cell therapy in an animal model of Alzheimer's disease
Date:3/26/2008

New Rochelle, NY, March 26, 2008A novel strategy based on targeted immune suppression using human umbilical cord blood cells may improve the pathology and cognitive decline associated with Alzheimers disease, based on the results of a study in a mouse model of this currently untreatable neurodegenerative condition, as described in a groundbreaking report in Stem Cells and Development (www.liebertpub.com/scd), a peer-reviewed journal published by Mary Ann Liebert, Inc (www.liebertpub.com). The paper will be available free online (http://www.liebertonline.com/toc/scd/0/0).

Following a series of low-dose infusions of human umbilical cord blood cells into mice with Alzheimers-like disease, the amount of amyloid- and -amyloid plaqueshallmarks of Alzheimers pathology in the brainwas markedly reduced. Amyloid- induces an inflammatory response in the brain associated with the interaction of CD40 and CD40L, two pro-inflammatory molecules.

Human umbilical cord blood cell therapy was associated with suppression of CD40-CD40L activity, suggesting that this therapeutic approach modulates the activity of the immune system, offering the potential to target the pathogenic inflammatory response that may contribute to a variety of degenerative conditions, including Alzheimers disease.

Jun Tan, PhD, MD, and colleagues from USF (Tampa), Yale University (New Haven, CT), Cedars-Sinai Medical Center (Los Angeles, CA), Saneron CCEL Therapeutics (Tampa, FL), and Saitama Medical School (Japan), concluded that human umbilical cord blood cell-induced disruption of the CD40-CD40L interaction may alleviate the key pathologic changes in the brain associated with Alzheimers disease in a report entitled, Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice.

Previously, challenging observations have reported phenomena suggesting the non-hematologic therapeutic potential of blood stem cells. What is novel about this paper is its application to Alzheimers disease, and a significant advance in characterizing the ameliorative mechanism of action says Graham C. Parker, PhD, Editor-in-Chief of Stem Cells and Development, and a research professor in The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related biology news :

1. Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice
2. Diabetes makes it hard for blood vessels to relax
3. Weill Cornell team discovers how brains own tPA helps regulate blood flow to neurons
4. High blood pressure in older adults traced to genes effects in blood vessels
5. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
6. MIT works toward engineered blood vessels
7. Blood pressure drug telmisartan shows powerful activity against stroke
8. Protein controls blood vessel formation, offers new drug target
9. Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream
10. Study of malaria parasite in patient blood finds distinct physiological states
11. Blood clotting protein linked to rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... 14, 2017  Wake Forest Baptist Medical Center today ... chief executive officer (CEO). Freischlag joins the medical center ... McConnell , M.D., who last year announced that he ... Center, after leading it since 2008.   ... Wake Forest Baptist,s academic health system, which includes Wake ...
(Date:2/9/2017)... -- The biomass boiler market report by Transparency Market ... globally in terms of revenue (US$ Mn) based on ... biomass boilers has been segmented on the basis of ... market based on feedstock type, has been segmented into ... crops, urban residues, and others. On the basis of ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 /PRNewswire/ ... point. Driven largely by the confluence of organizations, ... users, distaste for knowledge-based systems (password and challenge ... consumer, industrial, and government systems. The market is ... been a demarcation between consumer and enterprise uses ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today is providing ... its previously announced rights offering of up to ... stock and Series C Convertible Preferred Stock to ... As previously announced, the rights offering ...
(Date:2/24/2017)... N.J. , Feb. 24, 2017  Driven ... and biotechnology are now the fastest growing categories, ... Specialty Actives in Personal Care: Multi-regional Market ... research and management consulting firm Kline. ... bioprocesses that make them more effective for skin ...
(Date:2/24/2017)... Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading ... financial results for the fourth quarter and fiscal year of ... Total sales in the fourth quarter of ... 13.6% in USD terms to $77.6 million from $68.3 million ... profit increased by 13.3% to $46.8 million from $41.3 million ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 ... a leading digital health company, and Digital ... telemedicine and remote patient monitoring, announce they are ... DN Telehealth maximizes collaboration compatibility ... extending consultations beyond a physical clinical setting to ...
Breaking Biology Technology: